Astex
  • Discover Astex
    • Our Mission & Values
    • Our Leadership Team
      • UK – Discovery Research
        • Jeremy Carmichael
        • Harren Jhoti
        • Michelle Jones
        • Neil Jones
        • John Lyons
        • Chris Murray
        • David Rees
        • Nicola Wallis
        • Nicola Wilsher
      • USA – Product Development
        • Mohammad Azab
        • Martin Buckland
        • Harold N. Keer
        • Nipun Davar
        • Yong Hao
        • Joseph Iovino
        • Samuel Jason
        • Nancy Worrell
        • Patti Oto
    • Our History
    • Corporate Social Responsibility
  • R&D
    • Clinical Pipeline
      • Proprietary Products and Programs
        • Guadecitabine (SGI-110) DNMT inhibitor (Hematological Malignancies and Solid Tumors)
        • ASTX029 Extracellular Signal-Related Protein Kinases (ERK 1/2) Inhibitor (Solid Tumors)
        • Oral Decitabine and Cedazuridine (ASTX727) (Hematological Malignancies)
        • ASTX660 Dual IAP Antagonist (Solid Tumors & Lymphomas)
      • Partnered Products and Programs
        • Kisqali® (ribociclib) CDK4/6 inhibitor (Oncology)
        • Balversa® (erdafitinib) FGFr inhibitor (Oncology)
        • AZD5363 PKB/Akt Inhibitor (Oncology)
        • Multiple Targets and Therapeutic Areas
    • Pyramid™ Discovery Platform
    • Oncology and CNS Discovery
    • Sustaining Innovation Postdocs
  • Partnering
  • Our People & Culture
    • Career Opportunities
  • Media
    • Press Releases
    • Conferences & Meetings
    • Presentations & Publications
    • Interactive Scientific Resources
      • Interactive Software
    • Astex in the News
  • Contact
  • Search
  • Menu Menu
You are here: Home1 / Onalespib (AT13387) – HSP90 inhibitor2 / 20123 / 2012 EORTC: Activity of the HSP90 inhibitor AT13387 in ALK-driven tumor...

2012 EORTC: Activity of the HSP90 inhibitor AT13387 in ALK-driven tumor models

25 November 2012/in 2012, Onalespib (AT13387) – HSP90 inhibitor, Products

2012 EORTC: Activity of the HSP90 inhibitor AT13387 in ALK-driven tumor models

https://astx.com/wp-content/uploads/2019/11/logo_white.png 0 0 webadmin https://astx.com/wp-content/uploads/2019/11/logo_white.png webadmin2012-11-25 15:21:032016-11-25 15:21:392012 EORTC: Activity of the HSP90 inhibitor AT13387 in ALK-driven tumor models

© Astex Pharmaceuticals
All rights reserved

astex

Useful links

  • Home
  • Sitemap
  • Privacy Policy
  • Terms of Use
  • Legal

Member of the Otsuka Group

2012 Apoptosis and Cancer: A Potent XIAP And cIAP1 Dual Antagonist Is Effective...2012 ASH: Results from Dose Escalation Phase of Randomized Phase 1-2 FIH Study...
Scroll to top